Dermal injectable sterile composition
The present invention relates to a crosslinked hyaluronic acid gel which derives from the crosslinking of hyaluronic acid or of a salt thereof in the presence of at least an effective amount of at least one endogenous polyamine as a crosslinking agent, said crosslinking being carried out under conditions favorable to the coupling of said hyaluronic acid and of said endogenous polyamine(s).
1. A process for preparing a crosslinked gel of hyaluronic acid or a salt thereof, comprising the steps:
a) providing an aqueous gel of hyaluronic acid or of a salt thereof, in the noncrosslinked state,
b) bringing the gel obtained in step a) into contact with an effective amount of at least one endogenous polyamine to form a mixture, wherein said at least one endogenous polyamine is used in a content between 0.1% and 3% by number of moles of the at least one endogenous polyamine relative to the number of moles of hyaluronic acid,
c) crosslinking said mixture formed in step b), said crosslinking being carried out under conditions favourable to the covalent coupling of said hyaluronic acid and of said at least one endogenous polyamine to form a crosslinked hydrogel, and
d) recovering said crosslinked hydrogel, wherein said crosslinked hydrogel has a degree of modification of less than or equal to 1%, the degree of modification being the ratio between the number of moles of endogenous polyamine attached to the hyaluronic acid and the number of moles of hyaluronic acid forming said crosslinked hydrogel.
2. The process according to claim 1 , wherein said process also comprises a step e) of stopping the crosslinking, consisting of exposing the crosslinked hydrogel to conditions capable of stopping the crosslinking thereof, wherein the stopping step is carried out before, jointly with or after the recovering step d).
3. The process according to claim 1 , wherein the at least one endogenous polyamine is selected from the group consisting of spermidine, spermine, and a mixture thereof.
4. The process according to claim 1 , wherein the hyaluronic acid or a salt thereof is used in a content of between 0.5% and 12% by weight relative to the total weight of the mixture obtained at the end of step b).
5. The process according to claim 1 , wherein the crosslinking is carried out in the presence of a supplementary crosslinking agent.
6. The process according to claim 1 , wherein the coupling is carried out in the presence of at least one activator and, optionally combined with at least one other agent as auxiliary coupling agent.
7. The process according to claim 1 , wherein the process uses (i) sodium hyaluronate, (ii) spermine, as crosslinking agent, and (iii) 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in combination with N-hydroxybenzotriazole (HOBt), as, respectively, activator and auxiliary coupling agent.